Projected Growth of Next Generation Drug Conjugates Market to Reach $42.55 Billion by 2035 The Next Generation Drug Conjugates market is set for significant growth, projected to rise from $15.75 billion in 2026 to $42.55 billion by 2035, driven by innovative cancer therapies.

Projected Growth of Next Generation Drug Conjugates Market to Reach $42.55 Billion by 2035 #United_States #cancer_therapies #Delray_Beach #ENHERTU #Next_Generation_Drug_Conjugates

We aren't just statistics. We are mothers, daughters, and friends. We are out of time, and we are demanding change from AstraZeneca Wes Streeting @nhsengland @DaiichiSankyoUK
#metupuk #breastcancernow #Enhertu #enhertunow #her2low

🧵1/2

エンハーツ、HER2陽性早期乳がんの術後療法で米国FDAの優先審査に指定 再発・死亡リスクを53％低減 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

【ENHERTU Granted Priority Review in the US for Patients with HER2-Positive Early Breast Cancer】
エンハーツ、HER2陽性早期乳がんの術後療法で米国FDAの優先審査に指定 再発・死亡リスクを53％低減

stellanews.life/technology/9...

#Enhertu #BreastCancer #FDA #PriorityReview #HER2Positive #MedicalNews

Frontiers | Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 block...

www.frontiersin.org/journals/onc...

#Cancer #Kanser #BreastCancer #MemeKanseri #MedSky #OncSky #bcsm #enhertu #nerlynx #faslodex #taxol

Daiichi Sankyo gears up for five ADC launches in 2026

#DaiichiSankyo #ADCs #ADClaunches #Enhertu #Datroway #breastcancer #Oncology #antibodydrugconjugates #trastuzumabderuxtecan #datopotamabderuxtecan #pertuzumab #earlystagebreastcancer #triplenegativebreastcancer #Ifinatamabderuxtecan #IDXd #TROPIONBreast05study #ADCtechnology
zurl.co/TySHW

第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

第一三共、エンハーツが中国でHER2陽性胃がん二次治療に承認──DESTINY-Gastric04に基づく
ENHERTU (trastuzumab deruxtecan) approved in China for second-line HER2-positive gastric cancer based on DESTINY-Gastric04

stellanews.life/technology/8...

#GastricCancer #HER2 #ENHERTU #AntibodyDrugConjugate #DESTINYGastric04

EU starts review of first-line Enhertu for breast cancer EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.

The #EMA has started its review of #DaiichiSankyo and #AstraZeneca's #Enhertu as a first-line therapy for #HER2positive #breastcancer, setting up a possible approval later this year.

We’ve published an open letter to Health Secretary Wes Streeting calling for clarity, urgency and action on access to #Enhertu.

Read the full letter.

breastcancernow.org/media-assets...

Nadia Sawalha' fought to reverse a 'brutal' block on cancer drug Nadia Sawalha shared her heartbreak following the death of her friend after fighting to reverse a block on a cancer drug that could have extended her life.

Nadia Sawalha heartbreak following death of friend after fighting to reverse a block on a cancer drug that could have extended her life Loose Women star campaigned for use of #Enhertu available in Scotland and 14 countries, but not currently in England and Wales.
www.dailymail.co.uk/tvshowbiz/ar...

Senhwa Biosciences Targets Multi-Billion Dollar ADC Market with Innovative CX-5461 Therapy Senhwa Biosciences has launched a pivotal Phase 1b trial for CX-5461, combined with Enhertu®, focusing on HER2-positive tumors. This innovative study aims to enhance cancer treatment efficacy.

Senhwa Biosciences Targets Multi-Billion Dollar ADC Market with Innovative CX-5461 Therapy #None #ENHERTU #Senhwa_Biosciences #CX-5461

Roche's New FDA-Approved Tests Enhance HER2 Breast Cancer Diagnostics for ENHERTU Treatment Roche's PATHWAY HER2 and VENTANA HER2 tests have received FDA approval to identify patients with HER2-positive metastatic breast cancer eligible for ENHERTU treatment.

Roche's New FDA-Approved Tests Enhance HER2 Breast Cancer Diagnostics for ENHERTU Treatment #United_States #Tucson #HER2-positive #Roche_Diagnostics #ENHERTU

Nicole, who lives with HER2+ Metastatic Breast Cancer, shares her first-hand experience as a patient expert supporting the Enhertu submission.

📲 Link in bio to learn more about advocacy and how to get involved.

#METUPUK #PatientAdvocacy
#LivingWithMBC #HER2Positive #Enhertu

How well does Enhertu work in metastatic breast cancer? Official answer: Key Points In the DESTINY-Breast03 study in people with HER2-positive metastatic breast cancer, treatment with Enhertu...

#Enhertu showed strong results in metastatic breast cancer trials: 72% longer before progression vs Kadcyla in HER2+ patients. In HER2-low patients, cancer was controlled for 13.2 months vs 8.1 months with chemo, a 36% lower risk of progression or death.

Big news from the European Society for Medical Oncology! AstraZeneca & Daiichi Sankyo’s drug #Enhertu shows powerful results in early-stage breast cancer trials; moving closer to potential curative treatment. A real game changer. #BreastCancer #CancerResearch #TCSC

www.reuters.com/business/hea...

Enhertu pushes into early breast cancer, as antibody-drug conjugates move up the line Enhertu can help patients with breast cancer when given earlier in the disease, according to data presented at the ESMO Conference 2025.

#Enhertu being considered for eBC
"BERLIN — Enhertu has become a staple treatment in advanced breast cancer,but new data ... show the drug can have powerful benefits for patients when given earlier in the disease, opening the door to higher rates of cures."
www.statnews.com/2025/10/18/e...

Enhertu + Pertuzumab in 1L HER2+ MBC: FDA Priority Review FDA grants Priority Review to Enhertu+pertuzumab as first line treatment for HER2+ MBC decision expected Q1 2026.

FDA Priority Review for Enhertu + Pertuzumab in first-line HER2+ MBC

@fda.gov

oncodaily.com/fda-approval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Enhertu #Pertuzumab #HER2 #MBC #BreastCancer

How well does Enhertu work in metastatic breast cancer? Official answer: Key Points In the DESTINY-Breast03 study in people with HER2-positive metastatic breast cancer, treatment with Enhertu...

#Enhertu extends progression-free survival in metastatic breast cancer: 72% improvement vs Kadcyla in HER2-positive patients, 13.2 vs 8.1 months compared to chemotherapy in HER2-low patients (36% lower progression/death risk).

The HER2-Low Cancers Market: Future Growth and Key Therapies to Watch Through 2034 The HER2-low cancers market is projected to grow significantly, driven by new therapies like ENHERTU. Learn about market trends and key treatments.

The HER2-Low Cancers Market: Future Growth and Key Therapies to Watch Through 2034 #None #ADC_therapies #HER2-low_Cancers #ENHERTU

“What does Enhertu mean to you?”

For some in the METUPUK community, Enhertu brought stability, NEAD, and time for what matters. For others, side effects or progression meant a different reality. These stories show why access, innovation, and continued research are vital.

#METUPUK #Enhertu

DESTINY-Breast06: T-DXd outperforms chemo across all arms in HR+/HER2-low mBC. Higher PFS, cORR, and PFS2 seen vs CAPE, nab-pac, and paclitaxel. docwirenews.com/post/destiny... #ESMOBreast25 #bcsm #mBC #oncology #enhertu

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌

Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer.

#Onco404 #Cancer #Kanser #MedSky #AntibodyDrugConjugate #ADC #Enhertu #Trodelvy #Padcev #Kadcyla #Elahere #Mylotarg #Polivy #Vocabulary

HER2扩增转移性乳腺癌德曲妥珠单抗治疗复发获益奈拉替尼|单抗|患者|联合|拷贝数|乳腺癌|-健康界 本研究首次报道HER2-TKI联合方案在T-DXd耐药转移性乳腺癌中的显著疗效。

Neratinib-based treatment in post-T-DXd setting.

#breastcancer #memekanseri #enhertu #nerlynx

www.cn-healthcare.com/articlewm/20...

Study Links Body Composition to Trastuzumab Deruxtecan Dosing, Toxicity | Docwire News Higher fat mass and lower fat density linked to increased T-DXd dose reductions and toxicity in metastatic breast cancer.

New study links body fat composition to higher risk of dose reductions and toxicity with T-DXd in metastatic #BreastCancer. Personalized dosing strategies may be key. docwirenews.com/post/study-l... #HER2 #enhertu
@naturejournal.bsky.social

Enhertu Combo Boosts pCR in High-Risk HER2+ Early Breast Cancer: DESTINY-Breast11 Findings | Docwire News Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.

🚨 DESTINY-Breast11: #Enhertu + THP significantly improves pCR vs. standard chemo in high-risk #HER2+ early #breastcancer. First phase III data showing neoadjuvant benefit for trastuzumab deruxtecan. #oncology www.docwirenews.com/post/enhertu... @astrazeneca.bsky.social @daiichisankyo.bsky.social

Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer - The Cancer Letter The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in […]

#Enhertu demonstrates superior efficacy over standard of care in HER2+ metastatic breast cancer (@astrazeneca.bsky.social)
https://cancerletter.com/clinical-roundup/20250425_10a/

Enhertu: Σημαντική αποτελεσματικότητα στον μετασταστικό καρκίνο του μαστού Tο Enhertu επιβεβαιώνει τη θέση του ως νέα δυνητική θεραπεία πρώτης γραμμής για τον HER2-θετικό μεταστατικό καρκίνο του μαστού.

#Enhertu #καρκίνος_του_μαστού

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer | Docwire News Dr Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.

Dr Sara Nunnery breaks down the evolving HER2 classification system and the clinical impact of DESTINY-Breast06. Hear how #Enhertu is reshaping treatment for HR+/HER2-low #BreastCancer. Watch now ⬇️ docwirenews.com/post/reclass... #HER2Low #DESTINYBreast06 #Oncology #CancerResearch

Enhertu poised to move first line in HER2+ breast cancer New data could make HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first time.

News Catch-Up: Yesterday, #AstraZeneca and #DaiichiSankyo announced preparation of #regulatory filings that could make their #HER2-directed antibody-drug conjugate (#ADC) #Enhertu an option for previously untreated #breastcancer for the first time.

A new first-line treatment option is emerging in HER2+ breast cancer!

#Onco404 #OncSky #MedSky #Cancer #BreastCancer #MemeKanseri #Enhertu

How many days where you nauseated on #Enhertu? (Taking all the meds. They help.)
#Oncsky #CanSky #ThanksCancer #CancerBS